1-Methylpiperazine → Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid {3-(5-chloro-2-difluoromethoxyphenyl)-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-pyrazol-4-yl}amide
Reaction equation
[Cl:1][C:2]1[CH:3]=[CH:4][C:5]([O:37][CH:38]([F:40])[F:39])=[C:6]([C:8]2[C:12]([NH:13][C:14]([C:16]3[CH:17]=[N:18][N:19]4[CH:24]=[CH:23][CH:22]=[N:21][C:20]=34)=[O:15])=[CH:11][N:10]([CH2:25][C:26]([N:28]3[CH2:35][C@@H:34]4[C@@H](CN(C)C4)C3)=[O:27])[N:9]=2)[CH:7]=1.ClC1C=CC(OC(F)F)=C(C2[C:52](NC(C3C=NN4C=CC=NC=34)=O)=[CH:51][N:50]([CH2:65]C(O)=O)N=2)C=1.CN1CCNCC1>>[Cl:1][C:2]1[CH:3]=[CH:4][C:5]([O:37][CH:38]([F:40])[F:39])=[C:6]([C:8]2[C:12]([NH:13][C:14]([C:16]3[CH:17]=[N:18][N:19]4[CH:24]=[CH:23][CH:22]=[N:21][C:20]=34)=[O:15])=[CH:11][N:10]([CH2:25][C:26]([N:28]3[CH2:35][CH2:34][N:50]([CH3:65])[CH2:51][CH2:52]3)=[O:27])[N:9]=2)[CH:7]=1Participants
Reactant 3
Product 1
Procedure
The title compound was prepared in an analogous manner to cis-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid {3-(5-chloro-2-difluoromethoxyphenyl)1-[2-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2-yl)-2-oxoethyl]-1H-pyrazol-4-yl}amide using {3-(5-chloro-2-difluoromethoxy-phenyl)-4-[(pyrazolo[1,5-a]pyrimidine-3-carbonyl)amino]pyrazol-1-yl}acetic acid and methyl piperazine to afford the title compound as a pale yellow solid. LCMS (Method 5) [M+H]+=545.1, RT=2.89 min. 1H NMR (400 MHz, CDCl3) δ: (ppm) 9.85 (s, 1H), 8.78 (dd, 1H, J=1.6, 7.0 Hz), 8.71 (s, 1H), 8.56 (dd, 1H, J=1.7, 4.1 Hz), 8.41 (s, 1H), 7.69 (d, 1H, J=2.6 Hz), 7.41 (dd, 1H, J=2.6, 8.7 Hz), 7.28 (d, 1H, J=9.1 Hz), 7.00 (dd, 1H, J=4.2, 7.0 Hz), 6.47 (t, 1H, J=74.1 Hz), 5.04 (s, 2H), 3.72-3.65 (m, 2H), 3.57 (dd, 2H, J=4.8, 4.8 Hz), 2.47-2.39 (m, 4H), 2.31 (s, 3H).
Sources & evidence
- ORD record
- ord-e3a786d339b64ad2b907ecb4f8701fd4
- Source dataset
- uspto-grants-2016_05
- Patent number
- US09346815B2
Reaction notes
Loading…